2 Result: Argenx
Medical Breakthroughs: argenx's VYVGART Hytrulo and Pfizer's TALZENNA Garner FDA Approval
June 21st, 2023
argenx SE (Nasdaq: ARGX) has received approval from the U.S. Food and Drug Administration (FDA) for VYVGART Hytrulo, a subcutaneous injection used to treat generalized myasthenia gravis (gMG) in adult patients who test positive for anti-acetylcholine. Read more
Akebia Therapeutics, MDxHealth, Avis Budget, argenx, Five9, Inventiva: Analyst Upgrades and Initiations Point to Potential Upsides
May 31st, 2023
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company, received an upgrade from Neutral to Overweight by Piper Sandler, with the price target raised from $2 to $4. On Wednesday, $AKBA closed at $1.04, indicating a potential u. Read more
Want To Find Some News?
News By Industries
Recent Post
-
Micron Technology, Jabil, and Birkenstock Earnings Preview: What to Expect
December 15th, 2024Upcoming Earnings: Synopsys, AeroVironment, and nCino in Focus
December 01st, 2024Countdown to Earnings: Salesforce, Marvell Technology, and Okta Take the Stage
December 01st, 2024Fluence Energy, Agilent Technologies, and Woodward Earnings On Deck: A Preview
November 24th, 2024Earnings Preview: Walt Disney, Applied Materials, and Celcuity Take Center Stage
November 11th, 2024
Member Login